Metabotropic glutamate receptors in the basal ganglia motor circuit
暂无分享,去创建一个
P. Jeffrey Conn | Giuseppe Battaglia | F. Nicoletti | P. Conn | G. Battaglia | P. Conn | Ferdinando Nicoletti | M. Marino | Michael J. Marino
[1] Feng Liu,et al. Mechanism of Regulation of Casein Kinase I Activity by Group I Metabotropic Glutamate Receptors* , 2002, The Journal of Biological Chemistry.
[2] P. Popoli,et al. Permissive role of adenosine A2A receptors on metabotropic glutamate receptor 5 (mGluR5)‐mediated effects in the striatum , 2004, Journal of neurochemistry.
[3] Y. Smith,et al. NMDA-induced phosphorylation and regulation of mGluR5 , 2002, Pharmacology Biochemistry and Behavior.
[4] Charles J. Wilson,et al. Striatal interneurones: chemical, physiological and morphological characterization , 1995, Trends in Neurosciences.
[5] P. Worley,et al. Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins , 1999, Neuron.
[6] J. Bargas,et al. Cholinergic Modulation of Neostriatal Output: a Functional Antagonism between Different Types of Muscarinic Receptors Materials and Methods , 1999 .
[7] D. Lovinger. Trans-1-aminocyclopentane-1,3-dicarboxylic acid (t-ACPD) decreases synaptic excitation in rat striatal slices through a presynaptic action , 1991, Neuroscience Letters.
[8] S. Heinemann,et al. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems , 1999, Nature Neuroscience.
[9] P. Calabresi,et al. The modulation of calcium currents by the activation of mGluRs , 1996, Molecular Neurobiology.
[10] P. Calabresi,et al. Long-term synaptic depression in the striatum: physiological and pharmacological characterization , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[11] B Bioulac,et al. Subthalamic Nucleus Neurons Switch from Single-Spike Activity to Burst-Firing Mode , 1999, The Journal of Neuroscience.
[12] Y. Kawaguchi,et al. Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[13] P Jeffrey Conn,et al. Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse , 2003, The Journal of Neuroscience.
[14] S. Duty,et al. Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine‐treated rat , 2004, British journal of pharmacology.
[15] P. Greengard,et al. D(2) dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[16] G. V. van Rossum,et al. A 6-year follow-up study of oral function in shortened dental arches. Part II: Craniomandibular dysfunction and oral comfort. , 1994, Journal of oral rehabilitation.
[17] F. Gasparini,et al. Selective Activation of mGlu4 Metabotropic Glutamate Receptors Is Protective against Excitotoxic Neuronal Death , 2000, The Journal of Neuroscience.
[18] T. Hastings,et al. Biomedicine. Parkinson's--divergent causes, convergent mechanisms. , 2004, Science.
[19] M. Beal,et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Beal,et al. Experimental therapeutics in transgenic mouse models of Huntington's disease , 2004, Nature Reviews Neuroscience.
[21] F. Nicoletti,et al. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice , 2003, Neuropharmacology.
[22] W. Maragos,et al. Neuronal cell death in Huntington’s disease: a potential role for dopamine , 2000, Trends in Neurosciences.
[23] M. Beal,et al. Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.
[24] F. Nicoletti,et al. Interactions between Ephrin-B and Metabotropic Glutamate 1 Receptors in Brain Tissue and Cultured Neurons , 2005, The Journal of Neuroscience.
[25] A. Levey,et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users , 1996, Nature Medicine.
[26] G. Nappi,et al. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease , 2001, Annals of neurology.
[27] F. Nicoletti,et al. Neuroprotection by Glial Metabotropic Glutamate Receptors Is Mediated by Transforming Growth Factor-β , 1998, The Journal of Neuroscience.
[28] S. Traynelis,et al. Metabotropic Glutamate Receptors 1 and 5 Differentially Regulate CA1 Pyramidal Cell Function , 2001, The Journal of Neuroscience.
[29] M. Morari,et al. Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group‐II metabotropic and NMDA receptors , 2003, Journal of neurochemistry.
[30] P. Calabresi,et al. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia , 1996, Trends in Neurosciences.
[31] P Jeffrey Conn,et al. Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics. , 2002, Current drug targets. CNS and neurological disorders.
[32] A. Charara,et al. GABAB and group I metabotropic glutamate receptors in the striatopallidal complex in primates , 2000, Journal of anatomy.
[33] S. T. Kitai,et al. Firing patterns and synaptic potentials of identified giant aspiny interneurons in the rat neostriatum , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[34] J. Schiefer,et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease , 2004, Brain Research.
[35] L. Mao,et al. Selective activation of group I metabotropic glutamate receptors upregulates preprodynorphin, substance P, and preproenkephalin mRNA expression in rat dorsal striatum , 2001, Synapse.
[36] Y. Ben-Ari,et al. Quisqualate Metabotropic Receptors Modulate NMDA Currents and Facilitate Induction of Long‐Term Potentiation Through Protein Kinase C , 1992, The European journal of neuroscience.
[37] J. T. Greenamyre,et al. Parkinson's--Divergent Causes, Convergent Mechanisms , 2004, Science.
[38] F. Nicoletti,et al. Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[39] J. Cano,et al. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+‐induced neurotoxicity along with brain‐derived neurotrophic factor induction , 2001, Journal of neurochemistry.
[40] P. Greengard,et al. Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity , 2000, The Journal of Neuroscience.
[41] M. Merello,et al. Functional surgery for Parkinson's disease treatment: a structured analysis of a decade of published literature , 2004, British journal of neurosurgery.
[42] W. Spooren,et al. Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. , 2000, European journal of pharmacology.
[43] M R DeLong,et al. Models of basal ganglia function and pathophysiology of movement disorders. , 1998, Neurosurgery clinics of North America.
[44] K. Lange,et al. Glutamatergic drugs in Parkinson's disease. , 1994, Life sciences.
[45] K. Fuxe,et al. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[46] Y. Smith,et al. Distinct Functional Roles of the Metabotropic Glutamate Receptors 1 and 5 in the Rat Globus Pallidus , 2003, The Journal of Neuroscience.
[47] R. Albin,et al. Metabotropic Glutamate Agonist-Induced Rotation: A Pharmacological, FOS Immunohistochemical, and [14C]-2-Deoxyglucose Autoradiographic Study , 1997, The Journal of Neuroscience.
[48] D. Lovinger,et al. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. , 1995, Journal of neurophysiology.
[49] P. Calabresi,et al. Selective involvement of mGlu1 receptors in corticostriatal LTD , 2001, Neuropharmacology.
[50] P. Conn,et al. Distinct physiological roles of the Gq‐coupled metabotropic glutamate receptors co‐expressed in the same neuronal populations , 2002, Journal of cellular physiology.
[51] B. Hyman,et al. Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: A stereological estimate of neuronal loss , 1993, Neurobiology of Aging.
[52] O. Hassani,et al. Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states , 1997, Neuroscience.
[53] D. Standaert,et al. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[54] P. Conn,et al. Activation of group III mGluRs inhibits GABAergic and glutamatergic transmission in the substantia nigra pars reticulata. , 2001, Journal of neurophysiology.
[55] J. Pin,et al. Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.
[56] F. Nicoletti,et al. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors , 1999, Neuropharmacology.
[57] V. Lee,et al. Are Ubiquitination Pathways Central to Parkinson's Disease? , 2003, Cell.
[58] I. Vranesic,et al. (−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection , 2003, Neuropharmacology.
[59] Giuseppe Battaglia,et al. Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice , 2004, The Journal of Neuroscience.
[60] Roland Heckendorn,et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.
[61] M. O'Neill,et al. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease , 2002, Pharmacology Biochemistry and Behavior.
[62] P. Calabresi,et al. Targeting striatal cholinergic interneurons in Parkinson’s disease: Focus on metabotropic glutamate receptors , 2003, Neuropharmacology.
[63] J. Penney,et al. The Role of Group I and Group II Metabotropic Glutamate Receptors in Modulation of Striatal NMDA and Quinolinic Acid Toxicity , 2001, Experimental Neurology.
[64] P. Conn,et al. Group III Metabotropic Glutamate-Receptor-Mediated Modulation of Excitatory Transmission in Rodent Substantia Nigra Pars Compacta Dopamine Neurons , 2005, Journal of Pharmacology and Experimental Therapeutics.
[65] Andrzej Pilc,et al. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.
[66] L. Seiden,et al. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine , 1980, Brain Research.
[67] P. Calabresi,et al. Post-receptor mechanisms underlying striatal long-term depression , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[68] L. Mao,et al. Group I metabotropic glutamate receptor‐mediated calcium signalling and immediate early gene expression in cultured rat striatal neurons , 2003, The European journal of neuroscience.
[69] D. Schoepp,et al. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats , 1997, Neuroscience Letters.
[70] K. Mangano,et al. Activation of Group III Metabotropic Glutamate Receptors Inhibits the Production of RANTES in Glial Cell Cultures , 2002, The Journal of Neuroscience.
[71] L. Mao,et al. The protein phosphatase 1/2A inhibitor okadaic acid increases CREB and Elk‐1 phosphorylation and c‐fos expression in the rat striatum in vivo , 2004, Journal of neurochemistry.
[72] P. Conn,et al. Dopamine Modulates the Function of Group II and Group III Metabotropic Glutamate Receptors in the Substantia Nigra Pars Reticulata , 2002, Journal of Pharmacology and Experimental Therapeutics.
[73] B. Hyman,et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[74] S. Duty,et al. The group II metabotropic glutamate receptor agonist, DCG‐IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine‐treated rat , 2000, British journal of pharmacology.
[75] G. Collingridge,et al. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1 , 1994, Nature.
[76] A. Charara,et al. Ionotropic and metabotropic GABA and glutamate receptors in primate basal ganglia , 2001, Journal of Chemical Neuroanatomy.
[77] G. Collingridge,et al. Signal transduction pathways involved in the acute potentiation of NMDA responses by 1S,3R‐ACPD in rat hippocampal slices , 1993, British journal of pharmacology.
[78] Benjamin L Walter,et al. Surgical treatment for Parkinson's disease , 2004, The Lancet Neurology.
[79] Zheng-Xiong Xi,et al. The Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate , 2002, The Journal of Neuroscience.
[80] F. Moroni,et al. Type 2 Metabotropic Glutamate (mGlu) Receptors Tonically Inhibit Transmitter Release in Rat Caudate Nucleus: In Vivo Studies with (2S,1′S,2′S,3′R)‐2‐(2′‐carboxy‐3′‐phenylcyclopropyl)glycine, a New Potent and Selective Antagonist , 1997, The European journal of neuroscience.
[81] A. Dilella,et al. Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[82] K. Kullander,et al. Mechanisms and functions of eph and ephrin signalling , 2002, Nature Reviews Molecular Cell Biology.
[83] H. Kita,et al. Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus , 2003, Neuroscience.
[84] F. Gasparini,et al. Neuroprotective activity of metabotropic glutamate receptor ligands. , 2002, Advances in experimental medicine and biology.
[85] S. W. Davies,et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[86] Y. Smith,et al. Activation of Group I Metabotropic Glutamate Receptors Produces a Direct Excitation and Disinhibition of GABAergic Projection Neurons in the Substantia Nigra Pars Reticulata , 2001, The Journal of Neuroscience.
[87] J. Penney,et al. Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons , 1995, The Journal of comparative neurology.
[88] M. Amalric,et al. Simultaneous Blockade of Adenosine A2A and Metabotropic Glutamate mGlu5 Receptors Increase their Efficacy in Reversing Parkinsonian Deficits in Rats , 2004, Neuropsychopharmacology.
[89] K. Fuxe,et al. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP , 2005, Brain Research.
[90] P. Greengard,et al. Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[91] Antonio Pisani,et al. Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases , 2004, Progress in Neurobiology.
[92] D. S. Albers,et al. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism , 2005, Amino Acids.
[93] J. Cano,et al. DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury , 2002, Neuroscience.
[94] Roger L Albin,et al. Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons , 1998, Brain Research.
[95] M. Amalric,et al. Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism , 2002, The Journal of Neuroscience.
[96] J. T. Greenamyre,et al. Bioenergetics and glutamate excitotoxicity , 1996, Progress in Neurobiology.
[97] D. Laurie,et al. (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.
[98] P. Calabresi,et al. Metabotropic Glutamate 2 Receptors Modulate Synaptic Inputs and Calcium Signals in Striatal Cholinergic Interneurons , 2002, The Journal of Neuroscience.
[99] M. Beal,et al. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.
[100] D. Standaert,et al. Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia , 1998, The Journal of comparative neurology.
[101] D. Lovinger,et al. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum , 2002, Nature Neuroscience.
[102] P. Calabresi,et al. Endogenous ACh enhances striatal NMDA‐responses via M1‐like muscarinic receptors and PKC activation , 1998, The European journal of neuroscience.
[103] R. Albin,et al. The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation , 1998, Neuroscience.
[104] W. Poewe,et al. Low‐dose L‐dopa therapy in Parkinson's disease , 1986, Neurology.
[105] Greenamyre Jt,et al. Bioenergetics and glutamate excitotoxicity. , 1996 .
[106] G. Battaglia,et al. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective , 2000, Neuropharmacology.
[107] K. Perry,et al. Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum , 2000, Brain Research.
[108] M. Delong,et al. Functional and pathophysiological models of the basal ganglia , 1996, Current Opinion in Neurobiology.
[109] Y. Smith,et al. Differential Subcellular Localization of mGluR1a and mGluR5 in the Rat and Monkey Substantia Nigra , 2001, The Journal of Neuroscience.
[110] G. Nappi,et al. Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions , 2001, Neurological Sciences.
[111] D. Plenz,et al. Regulation of the Nigrostriatal Pathway by Metabotropic Glutamate Receptors during Development , 1998, The Journal of Neuroscience.
[112] F. Nicoletti,et al. Selective Blockade of mGlu5 Metabotropic Glutamate Receptors Is Protective against Methamphetamine Neurotoxicity , 2002, The Journal of Neuroscience.
[113] P. Greengard,et al. Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine , 2001, The Journal of Neuroscience.
[114] D. Lovinger,et al. Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses. , 2001, Journal of neurophysiology.
[115] P. Greengard,et al. Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[116] R. Porter,et al. Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum , 1993, Journal of neurochemistry.
[117] S. Hyman,et al. Addiction and the brain: The neurobiology of compulsion and its persistence , 2001, Nature Reviews Neuroscience.
[118] P. Conn,et al. Activation of groups I or III metabotropic glutamate receptors inhibits excitatory transmission in the rat subthalamic nucleus , 2001, Neuropharmacology.
[119] J. Grutsch,et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. , 1999, Journal of medicinal chemistry.
[120] J. Cooper,et al. Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.
[121] P. Löschmann,et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.
[122] M. Amalric,et al. Metabotropic Glutamate 5 Receptor Blockade Alleviates Akinesia by Normalizing Activity of Selective Basal-Ganglia Structures in Parkinsonian Rats , 2003, The Journal of Neuroscience.
[123] F. Gasparini,et al. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. , 1999, The Journal of pharmacology and experimental therapeutics.
[124] D. Lovinger,et al. Decreased Frequency But Not Amplitude of Quantal Synaptic Responses Associated with Expression of Corticostriatal Long-Term Depression , 1997, The Journal of Neuroscience.
[125] Y. Smith,et al. Activation of Metabotropic Glutamate Receptor 5 Has Direct Excitatory Effects and Potentiates NMDA Receptor Currents in Neurons of the Subthalamic Nucleus , 2000, The Journal of Neuroscience.
[126] G Bernardi,et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons , 2001, Neuroscience.
[127] Charles J. Wilson,et al. The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[128] Hui Zhang,et al. Glutamate Spillover in the Striatum Depresses Dopaminergic Transmission by Activating Group I Metabotropic Glutamate Receptors , 2003, The Journal of Neuroscience.
[129] F. Nicoletti,et al. The Neuroprotective Activity of Group-II Metabotropic Glutamate Receptors Requires New Protein Synthesis and Involves a Glial–Neuronal Signaling , 1997, The Journal of Neuroscience.
[130] J. Pin,et al. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. , 2002, Current drug targets. CNS and neurological disorders.
[131] P. Popoli,et al. Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid‐induced striatal toxicity: involvement of pre‐ and post‐synaptic mechanisms and lack of direct NMDA blocking activity , 2004, Journal of neurochemistry.
[132] P. Conn,et al. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. , 2000, Pharmacology & therapeutics.
[133] P. Conn,et al. Haloperidol-induced alteration in the physiological actions of group I mGlus in the subthalamic nucleus and the substantia nigra pars reticulata , 2002, Neuropharmacology.
[134] J. Sweatt,et al. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory , 2001, Journal of neurochemistry.
[135] C. Fiorillo,et al. Glutamate mediates an inhibitory postsynaptic potential in dopamine neurons , 1998, Nature.
[136] F. Vaglini,et al. (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice , 1994, Brain Research.
[137] T. Dawson,et al. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders , 2001, Trends in Neurosciences.
[138] P. Calabresi,et al. Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission , 2001, Molecular and Cellular Neuroscience.
[139] F. Nicoletti,et al. Retracted: Neuroprotection mediated by glial group‐II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol‐3‐kinase pathways , 2001, Journal of neurochemistry.
[140] P. Calabresi,et al. Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. , 2002, Brain : a journal of neurology.
[141] P. Somogyi,et al. Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS , 2002, Neuroscience.
[142] A. Levey,et al. Activation of Group II Metabotropic Glutamate Receptors Inhibits Synaptic Excitation of the Substantia Nigra Pars Reticulata , 2000, The Journal of Neuroscience.
[143] P Jeffrey Conn,et al. Glutamate Receptors and Parkinson’s Disease , 2003, Drugs & aging.
[144] G. Page,et al. Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes , 2001, Journal of neurochemistry.
[145] M. G. Lacey,et al. Metabotropic glutamate receptors depress glutamate‐mediated synaptic input to rat midbrain dopamine neurones in vitro , 1998, British journal of pharmacology.
[146] P. Calabresi,et al. Electrophysiological evidence for the presence of ionotropic and metabotropic excitatory amino acid receptors on dopaminergic neurons of the rat mesencephalon: an in vitro study. , 1992, Functional neurology.
[147] M. Pietraszek,et al. The role of metabotropic glutamate receptors in regulation of striatal proenkephalin expression: implications for the therapy of Parkinson′s disease , 2003, Neuroscience.